New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
05:11 EDTTKPYY, TEVATeva, Takeda Pharmaceutical agree to commercialize rasagilinein Japan
Teva Pharmaceutical (TEVA) and Takeda Pharmaceutical (TKPYY) have signed an agreement allowing Takeda to commercialize Teva’s innovative treatment for Parkinson’s disease, rasagiline in Japan. Developed by Teva, rasagiline tablets are approved in over 40 countries for the treatment of Parkinson’s disease. Teva developed this product and received its first approval in 2005 in Israel and Europe, and is currently working towards the acquisition of marketing approval of this product in Japan. Under the terms of the agreement, Takeda will develop rasagiline tablets for the Japanese market and submit a New Drug Application for registration of the product in Japan. The financial details of the agreement are confidential.
News For TEVA;TKPYY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 6, 2015
13:44 EDTTEVAMylan calls active after report of new Teva bid
Subscribe for More Information
12:31 EDTTEVATeva to bump bid for Mylan up to $86-$88 per share, Bloomberg says
Teva (TEVA) plans to raise its takeover bid for Mylan (MYL) to $86 to $88 per share from the $82 per share it offered in April, reported Bloomberg, citing people with knowledge of the matter, who said the sweetened bid could be announced as soon as this week. Shares of Mylan are up 0.8% to $70.69 following the report, while Teva shares are up 0.3% to $61.74. Reference Link
12:22 EDTTEVAMylan jumps after Bloomberg report of new Teva bid
Subscribe for More Information
12:18 EDTTEVATeva planning to raise Mylan bid to $86-$88/share, Bloomberg reports
Subscribe for More Information
July 1, 2015
08:30 EDTTEVATeva launches generic Aggrenox capsules in the U.S.
Teva announced the launch of generic Aggrenox capsules in the United States. Aspirin and extended-release dipyridamole capsules are used to lower the risk of stroke in people who have had a mini-stroke or stroke due to a blood clot. Aggrenox capsules had annual sales of approximately $457M in the United States, according to IMS data as of April.
08:11 EDTTEVATeva, Xenon provide update on TV-45070 Phase 2b study in OA pain
Subscribe for More Information
08:04 EDTTEVATeva, Xenon Pharmaceuticals provide update on TV-45070 Phase 2b study
Subscribe for More Information
08:01 EDTTEVATeva CEO: Pharma industry undergoing “very big shakeup,” Globes reports
Subscribe for More Information
June 30, 2015
08:27 EDTTEVAPerrigo deal for Roxane would make Mylan fight harder, says Citi
Subscribe for More Information
June 26, 2015
10:38 EDTTEVACourt revives lawsuit over GlaxoSmithKline Lamictal drug, Bloomberg reports
Subscribe for More Information
June 25, 2015
13:59 EDTTEVATeva initiated with a Hold at HSBC
Subscribe for More Information
12:52 EDTTEVAEU to decide by July 29 on Mylan's bid for Perrigo, Reuters reports
Subscribe for More Information
08:05 EDTTEVATeva, Active Biotech say patient enrollment finalized for CONCERTO trial
Subscribe for More Information
June 24, 2015
08:04 EDTTEVATeva launches PainMatters.com to support ‘responsible pain management’
Subscribe for More Information
June 23, 2015
14:16 EDTTEVABMO Capital sees strong fundamentals in Perrigo regardless of Mylan deal
Shares of Perrigo (PRGO) are trading higher intraday after BMO Capital Markets initiated coverage of the stock with an Outperform rating. The research firm is bullish on the shares regardless of whether Mylan's bid for the company succeeds, saying Perrigo is well-positioned to ride momentum in reduced-price healthcare. WHAT'S NEW: BMO Capital Markets' David Maris initiated coverage of Perrigo with an Outperform rating and a $246 price target. Maris cited the company's 70%-plus market share in store- and private-label brands, as well as its roughly $1B annual sales in the generics space. The analyst believes Perrigo will see continued benefit from larger trends driving consumer-centric healthcare and the curtailing of medical costs. WHAT'S NOTABLE: BMO Capital Markets noted that two upcoming Tysabri-related events are not accounted for by the Street, giving rise to a "significant" undervaluing of the shares. Mylan (MYL) has submitted multiple unsolicited offers for Perrigo, and while the likelihood of the deal seems low given Perrigo's numerous rejections and Teva's (TEVA) 4.61% blocking stake in Mylan. BMO Capital remarked that a failed deal should see "limited downside" for Perrigo. There could certainly be near-term volatility if a Mylan agreement doesn't materialize, but the analyst was confident in the well-positioned company's ability to deliver on both earnings per share and cash flow. PRICE ACTION: Shares of Perrigo are up nearly 2% in afternoon trading. The company saw a nearly 25% leap following Mylan's initial offer on April 8, though it has since dipped from that high.
13:10 EDTTKPYYNestle appoints Takeda’s Roger as CFO, effective July 1
Subscribe for More Information
08:49 EDTTEVAMylan CFO to meet with Tel Aviv bourse head Wednesday, Reuters says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use